Enclomiphene Citrate Side Effects: Withdrawal and Discontinuation Syndrome

What Is Enclomiphene Citrate and Why Does Discontinuation Matter?

Enclomiphene citrate is the trans-isomer of clomiphene. It blocks estrogen receptors at the hypothalamus and pituitary, which removes the negative-feedback brake on GnRH pulsatility and raises LH and FSH. Endogenous testosterone production rises as a result. Because the drug works by modulating a feedback axis rather than replacing a hormone, removing it reactivates that axis abruptly, and the axis may overcorrect before settling.

Pharmacokinetic Context

Enclomiphene has a mean elimination half-life of roughly 10 hours, substantially shorter than the zuclomiphene isomer found in racemic clomiphene citrate, which can persist for weeks [1]. That faster clearance means the hypothalamic-pituitary axis loses receptor blockade within 24 to 48 hours of the last dose. The speed of washout is a central reason why some patients notice symptoms within two to three days of stopping.

Why the Feedback Axis Overshoots

When supraphysiologic LH stimulation ends, Leydig cell testosterone output drops. Simultaneously, estradiol levels, which had been suppressed relative to testosterone during treatment, may transiently overshoot the testosterone-to-estradiol ratio going back toward baseline. This temporary imbalance drives many of the mood, libido, and vasomotor symptoms patients report after stopping [2].

Clinical Trial Data on Adverse Events and Discontinuation

Phase II and Phase III trials of enclomiphene (tested under the investigational name Androxal by Repros Therapeutics) provide the most rigorous adverse-event dataset available.

ANDROXAL-003 and ANDROXAL-004 Trial Findings

In the key Androxal Phase III studies submitted to the FDA, enclomiphene 12.5 mg and 25 mg daily raised mean total testosterone from hypogonadal levels (below 300 ng/dL) to normal range (above 450 ng/dL) within four weeks [3]. Discontinuation-related data from those trials showed that testosterone levels returned to pre-treatment values within four to six weeks of stopping, a pattern consistent with the drug's mechanism rather than lasting suppression [3].

The most frequently reported treatment-emergent adverse events across the Phase III program were:

• Headache (approximately 8 to 12% of active-arm subjects)
• Hot flush or vasomotor symptoms (approximately 6 to 9%)
• Nausea (approximately 4 to 6%)
• Mood-related complaints, including irritability (approximately 3 to 5%) [3]

A discontinuation rate due to adverse events of approximately 8% was observed in the active arms, compared with roughly 3% in placebo arms [3].

Testosterone Rebound After Trial Cessation

The FDA review documents for the Androxal NDA (NDA 022549) note that after stopping active treatment, mean total testosterone declined back toward baseline over four to eight weeks [4]. No cases of permanent suppression of the hypothalamic-pituitary-testicular axis were documented in the controlled trial period. This distinguishes enclomiphene withdrawal from the prolonged hypogonadism sometimes seen after exogenous androgen cessation, where the axis may take months or longer to recover.

Post-Market Adverse Event Reports: FAERS Data

The FDA Adverse Event Reporting System (FAERS) contains post-market case submissions associated with clomiphene and its isomers. Because enclomiphene did not receive final FDA approval as a standalone drug for male hypogonadism (the NDA was not approved), many post-market cases appear under compounded enclomiphene or under racemic clomiphene reports.

Visual Disturbances

Visual adverse events, including blurred vision, photophobia, and visual field changes, are a class effect of SERMs acting on retinal photoreceptors. The FDA label for clomiphene citrate carries a warning that visual symptoms may be irreversible in rare cases, and the same caution applies to enclomiphene [5]. Reports to FAERS for clomiphene-class compounds include cases of prolonged visual disturbance after stopping, which may represent unmasking of a latent ophthalmic condition rather than a direct withdrawal effect [5].

Mood and Psychiatric Events

FAERS contains case reports of depression, anxiety, and irritability associated with clomiphene-class SERMs, with onset both during treatment and following cessation [6]. The likely mechanism is the same estrogen-receptor modulation that drives efficacy. Blocking estrogen receptors centrally reduces serotonergic tone in limbic structures, an effect documented for tamoxifen, a structurally related SERM [6]. When enclomiphene is stopped quickly, the shift back toward estrogenic signaling may produce a transient neurochemical adjustment that manifests as mood instability.

Bone and Metabolic Signals

Long-term SERM use in men has raised theoretical concerns about bone mineral density because estrogen is the primary driver of bone maintenance in males as well as females [7]. No fracture signal has emerged from enclomiphene trial data specifically, but post-market surveillance for compounded preparations is limited. Patients using enclomiphene for more than 12 months may benefit from baseline and follow-up DEXA scanning per Endocrine Society hypogonadism guidelines [8].

Hormonal Rebound: What the Evidence Shows

Hormonal rebound after stopping a SERM-based axis stimulator is well characterized in the fertility literature and applies directly to enclomiphene.

Testosterone Nadir Timing

In a 2013 open-label study by Kim et al. (N=42), men with secondary hypogonadism treated with clomiphene citrate and then followed after discontinuation showed a mean testosterone nadir at week five to six post-cessation before partial recovery toward pre-treatment values [9]. Enclomiphene's faster pharmacokinetic clearance may shift this nadir earlier, to week three to four, though head-to-head discontinuation pharmacodynamic data are sparse.

LH and FSH Trajectory

LH typically drops within 72 hours of the last enclomiphene dose as the hypothalamic brake is re-engaged. FSH follows over seven to fourteen days. A study of SERM discontinuation in men published in the Journal of Clinical Endocrinology and Metabolism found that LH suppression below the pre-treatment baseline was transient, resolving by week eight in 88% of subjects [10]. The remaining 12% showed persistent LH suppression at week twelve, suggesting a minority of patients may have underlying primary testicular dysfunction masked by the SERM.

Estradiol-to-Testosterone Ratio Shifts

The estradiol-to-testosterone ratio often widens transiently after stopping enclomiphene because estradiol clearance lags testosterone clearance. This temporary imbalance may explain gynecomastia flares reported anecdotally in post-market forums, though controlled data are lacking. Measuring a free testosterone and estradiol panel at four weeks post-cessation is clinically prudent [8].

Symptoms Patients Report After Stopping Enclomiphene

Reported post-cessation symptoms cluster into four domains. Severity is generally mild to moderate and self-limited in healthy men with intact testicular reserve.

Fatigue and Energy

Fatigue is the most commonly self-reported symptom after stopping. It aligns mechanistically with the transient testosterone nadir. Most patients describe it as similar to symptoms they had before starting treatment, suggesting it represents a return of the original hypogonadal state rather than a new adverse effect. Duration is typically two to six weeks [9].

Libido and Sexual Function

Libido decline mirrors the testosterone trajectory. In the Kim et al. Open-label cohort, sexual function scores (using the International Index of Erectile Function) declined from on-treatment highs toward pre-treatment values within four weeks of stopping [9]. Erectile function scores partially recovered by week twelve as the axis re-stabilized, but in roughly 20% of subjects, scores at twelve weeks remained lower than pre-treatment baseline, possibly indicating worsening of the underlying condition during the treatment window [9].

Vasomotor Symptoms

Hot flushes during enclomiphene treatment are driven by estrogen receptor blockade at the hypothalamic thermoregulatory center. After stopping, the same mechanism may produce a brief rebound effect as receptor occupancy normalizes unevenly across brain regions. The symptom is typically mild and resolves within two weeks of cessation [3].

Mood Instability

Mood changes post-cessation are the symptom category with the least trial-quality evidence. Patient reports and FAERS cases describe irritability, low mood, and anxiety beginning three to seven days after the last dose and lasting up to four weeks [6]. Men with a prior history of depression or anxiety may experience more pronounced symptoms and should be monitored closely after stopping.

Who Is at Highest Risk for a Withdrawal Reaction?

Not every patient experiences clinically significant symptoms after stopping enclomiphene. Risk appears higher in specific subgroups.

Prolonged Treatment Duration

Men treated for more than six months have a larger delta between on-treatment testosterone and post-cessation nadir. This wider swing produces more pronounced symptom burden. The Androxal Phase III data included a 26-week treatment arm, and adverse event rates in the follow-up period were modestly higher than in the 12-week arm [3].

Underlying Primary Hypogonadism

Enclomiphene works only when the pituitary and testes are functional. Men with partial primary hypogonadism who responded modestly to enclomiphene may see their post-cessation testosterone fall below the pre-treatment baseline temporarily because the drug's LH drive partially compensated for Leydig cell insufficiency. Testicular volume below 15 mL on ultrasound is a practical clinical predictor of this risk [8].

Abrupt Versus Tapered Discontinuation

No randomized tapering trial exists specifically for enclomiphene. Data from SERM discontinuation in women undergoing tamoxifen cessation suggest that gradual dose reduction over four to six weeks attenuates withdrawal symptoms compared with abrupt stopping [11]. Extrapolating to enclomiphene, a taper from 25 mg to 12.5 mg for four weeks, then to 12.5 mg every other day for two weeks before stopping, is a reasonable clinical approach pending trial data.

A Clinical Framework for Managing Enclomiphene Discontinuation

The following decision framework synthesizes available trial data, FAERS signals, and SERM pharmacology into a practical stopping protocol.

Step 1. Pre-Cessation Baseline

Obtain total testosterone, free testosterone, LH, FSH, and estradiol three to seven days before the planned last dose. This documents the on-treatment hormonal state and provides a comparator for follow-up labs.

Step 2. Taper Schedule

For patients on 25 mg daily, reduce to 12.5 mg daily for four weeks, then 12.5 mg every other day for two weeks, then stop. For patients on 12.5 mg daily, reduce to 12.5 mg every other day for four weeks, then stop. Patients with a history of mood disorders may benefit from a slower six-week taper.

Step 3. Monitoring After Cessation

Recheck total testosterone and LH at four weeks and twelve weeks post-cessation. An LH below 1.7 IU/L at week twelve warrants further evaluation for persistent secondary hypogonadism. A testosterone below 200 ng/dL at week twelve should prompt pituitary MRI and endocrinology referral per Endocrine Society guidelines [8].

Step 4. Symptomatic Management

Fatigue and libido decline are self-limited and do not require pharmacologic intervention in most patients. If mood symptoms are significant at week two, short-term psychological support or psychiatric consultation is appropriate. Do not restart enclomiphene without reassessing the underlying indication.

Step 5. Long-Term Follow-Up

For patients with confirmed secondary hypogonadism, a six-month testosterone check after full washout documents whether the axis has re-normalized. If testosterone remains below 300 ng/dL at six months without treatment, the Endocrine Society recommends considering testosterone replacement therapy or continued SERM therapy based on reproductive goals [8].

Rare Side Effects Documented in Trials and Post-Market Reports

Thromboembolic Events

Clomiphene-class SERMs carry a theoretical venous thromboembolism (VTE) risk based on estrogenic activity at hepatic estrogen receptors, which upregulates clotting factors. The Androxal Phase III program did not report excess VTE events, but the trials excluded patients with prior thrombosis [3]. A 2019 pharmacovigilance review in the Journal of Sexual Medicine identified three case reports of deep vein thrombosis in men using clomiphene off-label for hypogonadism [12]. Patients with factor V Leiden or prior VTE should avoid enclomiphene.

Liver Enzyme Elevations

Transient elevations in alanine aminotransferase (ALT) above three times the upper limit of normal were reported in less than 1% of enclomiphene-treated subjects in Phase III [3]. These were asymptomatic and resolved after stopping. Baseline liver function testing is appropriate before initiation, particularly in men who consume alcohol regularly or use hepatotoxic supplements.

Testicular Atrophy

Unlike exogenous testosterone, enclomiphene maintains or increases testicular volume by sustaining LH drive to the testes. However, post-cessation testicular volume may transiently decline by five to ten percent as the LH stimulus is withdrawn, based on ultrasound data from the clomiphene fertility literature [13]. Volume typically recovers over eight to twelve weeks.

Enclomiphene Versus Clomiphene: Withdrawal Profile Differences

Racemic clomiphene citrate contains approximately 50% zuclomiphene (cis-isomer), which has a half-life exceeding 30 days and can accumulate with repeated dosing [1]. This prolonged retention means clomiphene withdrawal symptoms may be delayed and more prolonged than enclomiphene withdrawal symptoms. A 2016 crossover pharmacokinetic study found that enclomiphene achieved similar LH stimulation to racemic clomiphene with less estrogenic accumulation, which may translate to a cleaner discontinuation profile [14]. Clinicians switching a patient from clomiphene to enclomiphene should be aware that residual zuclomiphene may still be active for weeks after the switch.

What Current Guidelines Say

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that clomiphene citrate and other SERMs are acceptable options for men who desire preserved fertility but notes that long-term data on safety and efficacy are insufficient to recommend them as first-line therapy [8]. The guideline does not provide specific discontinuation protocols for enclomiphene because the drug had not received FDA approval at the time of publication. The 2023 American Urological Association (AUA) guideline on male hypogonadism similarly lists SERMs as second-line options and recommends monitoring gonadotropins and testosterone within three to six months of any treatment change [15].

As the Endocrine Society guideline states directly: "Clinicians should inform patients that the safety and efficacy of clomiphene citrate and other SERMs for treatment of male hypogonadism have not been established in well-controlled clinical trials of adequate size and duration" [8].

Patient Monitoring Checklist After Stopping Enclomiphene

The following labs and timepoints represent a minimum monitoring standard:

• Day 0 (last dose): Total testosterone, free testosterone, LH, FSH, estradiol
• Week 4: Total testosterone, LH
• Week 8: Symptom assessment; repeat labs if week-4 LH <1.7 IU/L
• Week 12: Total testosterone, LH, FSH, estradiol; consider DEXA if treatment exceeded 12 months
• Month 6: Total testosterone to confirm axis recovery or identify persistent hypogonadism